Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center

BACKGROUND: Biological therapies have changed the landscape of pharmacological management of ulcerative colitis (UC). However, a large proportion of patients do not respond to biologics, lose their response over time, or present adverse drug events. This study aims to assess therapeutic response and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagnon, Ann-Lorie, Beauchesne, William, Tessier, Laurence, David, Charles, Berbiche, Djamal, Lavoie, Alexandre, Michaud-Herbst, Alban, Tremblay, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802068/
https://www.ncbi.nlm.nih.gov/pubmed/36777273
http://dx.doi.org/10.1093/crocol/otab049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802068/
https://www.ncbi.nlm.nih.gov/pubmed/36777273
http://dx.doi.org/10.1093/crocol/otab049

Ejemplares similares